By: Jeff Minerd From: medpagetoday.com A cost-effectiveness study provided guidance on optimal treatment sequencing of single-agent chemotherapy options for women with metastatic breast cancer. “In this setting where multiple single-agent chemotherapy options are recommended by clinical guidelines and share similar survival and adverse event trajectories, treatment sequencing approaches that minimize costs early may improve the value of care,” said Stephanie …
“Stage Zero” Breast Cancer: What’s the Optimal Treatment for DCIS?
From: cuimc.columbia.edu Before the advent of routine mammography, DCIS (ductal carcinoma in situ) was rarely detected. But today, DCIS accounts for 20% of breast cancer diagnoses and would be the fifth most common cancer in women if classified independently. Often called “stage zero breast cancer,” DCIS growths are confined to the inside of the breast’s milk ducts, and many never …
Consensus Called for When Choosing Optimal Treatment for Breast Cancer–Related Lymphedema
By: Maggie L. Shaw From: ajmc.com More than 20% of breast cancer survivors are severely affected by upper-limb breast cancer–related lymphedema (BCRL), which has debilitating adverse effects that include depression, chronic pain, functional impairment, recurrent skin infections, poor body image, and anxiety—all having an impact on overall long-term health-related quality of life (HRQOL). The 2 principal treatment modalities are complex …